The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature
Abstract
There is no clear consensus regarding the frequency (and hence, the risk), of dyskinesias or motor fluctuations during chronic levodopa therapy for Parkinson's disease (PD). Multiple clinical series have tabulated these frequencies since the advent of levodopa over 30 years ago. We were interested in determining: (1) the aggregate frequency figures in the existing literature; and (2) how clinical series from the early levodopa era, which included patients with longer durations of parkinsonism, compare to more recent (modern era) series. We searched MEDLINE for all English language publications reporting the cumulative frequency of levodopa‐induced dyskinesias or motor fluctuations during discrete intervals of treatment. This generated 2,478 publications spanning 1966 through September 2000. Papers with appropriate titles or abstracts were reviewed; reference lists from published clinical series were a source of additional papers for review. This ultimately yielded 74 publications with adequate data, relating to 112 intervals of levodopa treatment. Series that included patients with PD‐onset well before levodopa availability (pre‐levodopa era) were separately analyzed from all subsequent series. Series were grouped by duration of levodopa therapy and the median frequencies of dyskinesias and motor fluctuations were tabulated for each group. The data were analyzed both with and without adjustment for the number (N) in each series. Among series containing pre‐levodopa era patients, the median dyskinesia frequency was already 50% by 5–6 months of treatment. This contrasts with the modern era series where dyskinesias were reported later in treatment. The median dyskinesia frequency was slightly less than 40% by 4–6 years of levodopa therapy among modern era patients. Motor fluctuations (wearing‐off) were not tabulated in most of the early levodopa series. Among modern era reports, motor fluctuations were nil during the first year of levodopa therapy but were experienced by approximately 40% of patients by 4–6 years of treatment. Similar results were found when the analyses were restricted to only prospective studies where levodopa motor complications were targeted outcome measures. The conclusions reached were: (1) patients from the pre‐levodopa era experienced dyskinesias much earlier during levodopa treatment than modern era patients, perhaps because of longer durations of pre‐existing PD; (2) in the present era, patients treated with levodopa therapy for 4–6 years have approximately a 40% likelihood of experiencing motor fluctuations and a risk of dyskinesias just short of 40%; and (3) these findings represent incident data and the prevalence of clinically important morbidity may be substantially less. © 2001 Movement Disorder Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Treatment of Parkinsonism With Levodopa
Yahr, M. D., Duvoisin, R. C., Schear, M. J., Barrett, R. E., & Hoehn, M. M. (1969) · Archives of Neurology · doi:10.1001/archneur.1969.00480160015001 · Cited by 604
The “On–Off” Phenomenon in Parkinson’s Disease: Relation to Levodopa Absorption and Transport
Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., & Anderson, J. L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402233100802 · Cited by 554
Young onset Parkinson's disease
Quinn, N., Critchley, P., & Marsden, C. D. (1987) · Movement Disorders · doi:10.1002/mds.870020201 · Cited by 443
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
Barbeau, A. (1969) · PubMed · Cited by 410
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Rinne, U., Bracco, F., Chouza, C., Dupont, E., Gershanik, O., Masso, J. M., Montastruc, J., & Marsden, C. (1998) · Drugs · doi:10.2165/00003495-199855001-00004 · Cited by 324
Cited by
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70293-x · Cited by 716
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Jankovic, J. (2005) · Movement Disorders · doi:10.1002/mds.20458 · Cited by 547
Molecular mechanisms of L-DOPA-induced dyskinesia
Jenner, P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2471 · Cited by 523
Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215250.82576.87 · Cited by 499
Warren Olanow, C., Kieburtz, K., Rascol, O., Poewe, W., Schapira, A. H., Emre, M., Nissinen, H., Leinonen, M., Stocchi, F., & Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) Investigators (2013) · Movement Disorders · doi:10.1002/mds.25364 · Cited by 484
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G. (2007) · Movement Disorders · doi:10.1002/mds.21475 · Cited by 464
Epidemiology of Parkinson’s disease
Alves, G., Forsaa, E. B., Pedersen, K. F., Dreetz Gjerstad, M., & Larsen, J. P. (2008) · Journal of Neurology · doi:10.1007/s00415-008-5004-3 · Cited by 363
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough
Lang, A. E., & Obeso, J. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00740-9 · Cited by 345
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., & Lang, A. E. (2018) · Annals of Neurology · doi:10.1002/ana.25364 · Cited by 340
Cilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Ferroptosis and cell death mechanisms in Parkinson's disease
Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Ayton, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.01.004 · Cited by 338
Limitations of current Parkinson's disease therapy
Rascol, O., Payoux, P., Ory, F., Ferreira, J. J., Brefel-Courbon, C., & Montastruc, J.-L. (2003) · Annals of Neurology · doi:10.1002/ana.10513 · Cited by 337
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias
Morgante, F., Espay, A. J., Gunraj, C., Lang, A. E., & Chen, R. (2006) · Brain · doi:10.1093/brain/awl031 · Cited by 327
Levodopa for the Treatment of Parkinson's Disease
LeWitt, P. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0800326 · Cited by 312
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Katzenschlager, R., Hughes, A., Evans, A., Manson, A. J., Hoffman, M., Swinn, L., Watt, H., Bhatia, K., Quinn, N., & Lees, A. J. (2005) · Movement Disorders · doi:10.1002/mds.20276 · Cited by 286
Review: Deep brain stimulation in Parkinson’s disease
Groiss, S. J., Wojtecki, L., Südmeyer, M., & Schnitzler, A. (2009) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285609339382 · Cited by 280
Suchowersky, O., Reich, S., Perlmutter, J., Zesiewicz, T., Gronseth, G., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215437.80053.d0 · Cited by 280
Clinical spectrum of levodopa‐induced complications
Aquino, C. C., & Fox, S. H. (2015) · Movement Disorders · doi:10.1002/mds.26125 · Cited by 270
Cenci, M. A., & Lundblad, M. (2007) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0925s41 · Cited by 266
Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia
Cenci, M. A. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.005 · Cited by 265
Hauser, R. A., Rascol, O., Korczyn, A. D., Jon Stoessl, A., Watts, R. L., Poewe, W., De Deyn, P. P., & Lang, A. E. (2007) · Movement Disorders · doi:10.1002/mds.21743 · Cited by 252
Hallett, P. J., Dunah, A. W., Ravenscroft, P., Zhou, S., Bezard, E., Crossman, A. R., Brotchie, J. M., & Standaert, D. G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.11.008 · Cited by 192
Nicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Quik, M., Cox, H., Parameswaran, N., O'Leary, K., Langston, J. W., & Di Monte, D. (2007) · Annals of Neurology · doi:10.1002/ana.21203 · Cited by 133
Serotonin–dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias
CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00922-9 · Cited by 131
Systematic review on factors associated with medication non-adherence in Parkinson's disease
Daley, D. J., Myint, P. K., Gray, R. J., & Deane, K. H. O. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.09.004 · Cited by 124
Fuentes, R., Petersson, P., & Nicolelis, M. A. L. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07417.x · Cited by 85
Stacy, M., & Hauser, R. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-006-0554-y · Cited by 83
Bagetta, V., Sgobio, C., Pendolino, V., Del Papa, G., Tozzi, A., Ghiglieri, V., Giampà, C., Zianni, E., Gardoni, F., Calabresi, P., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2664-12.2012 · Cited by 74
How do you treat motor complications in Parkinson's disease: medicine, surgery, or both?
Fahn, S. (2009) · Annals of Neurology · doi:10.1002/ana.21453 · Cited by 66
Stacy, M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0424-5 · Cited by 66
Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease
Poewe, W., & Mahlknecht, P. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2019.12.002 · Cited by 60
Chotibut, T., Meadows, S., Kasanga, E. A., McInnis, T., Cantu, M. A., Bishop, C., & Salvatore, M. F. (2017) · Movement Disorders · doi:10.1002/mds.27077 · Cited by 56
Matsuo, K., Cheng, A., Yabuki, Y., Takahata, I., Miyachi, H., & Fukunaga, K. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.029 · Cited by 43
Dysfunction of serotonergic neurons in Parkinson’s disease and dyskinesia
Vegas-Suarez, S., Paredes-Rodriguez, E., Aristieta, A., Lafuente, J. V., Miguelez, C., & Ugedo, L. (2019) · International Review of Neurobiology · doi:10.1016/bs.irn.2019.06.013 · Cited by 26
Nero, H., Benka Wallén, M., Franzén, E., Conradsson, D., Ståhle, A., & Hagströmer, M. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160826 · Cited by 18
Thomsen, M., Stoica, A., Christensen, K. V., Fryland, T., Mikkelsen, J. D., & Hansen, J. B. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114209 · Cited by 8
New trends in advanced Parkinson disease stage therapy
Kolesárová, M., Franko, O., Kolesár, D., Gažová, A., & Kyselovič, J. (2023) · Česká a slovenská farmacie · doi:10.5817/csf2023-1-37 · Cited by 2
Metadata
- Authors
- Ahlskog, J. E., & Muenter, M. D.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2001-05
- Volume
- 16
- Issue
- 3
- Pages
- 448-458
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2115222037
- Cited by
- 1,454
- References
- 47
- FWCI
- 16.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.